28.09.2017 • TopicsTemple UniversitySGSSenn Chemicals

M&A in Pharma and CRO/CMO Industry

(c) cacaroot/Fotolia
(c) cacaroot/Fotolia

Challenges caused by a merger or an acquisition can be manifold, no matter whether it is your own organization that is going through M&A and the integration phase or any of your outsourcing partners or customers. Distractions or disruptions are pre-programmed and sometimes inevitable, thus, it gets hard to maintain business as usual. In such a phase it is important not to lose focus on customer relationship and ongoing projects. CHEManager International asked executives and opinion leaders in the chemical and pharmaceutical market to share their experience and advice. For instance, we wanted to know:

  • Will the consolidation in the pharmaceutical industry level off or will it even intensify?
  • Does the consolidation in the pharma industry create a necessity for CROs/CMOs to consolidate?
  • How big of an issue is a merger or an acquisition for ongoing projects?
  • How can outsourcing partners maintain their focus and guarantee confidentiality in their projects?

Read the insightful answers of the experts here

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read